



IFW

PATENT
Attorney Docket 057084-5013

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Alexander Ian Smith <i>et al.</i>)	
)	
U.S. Application 10/520,624)	Group Art Unit: 1652
)	
U.S. National Phase of PCT/AU03/000892)	Examiner: Not Assigned
)	
International Filing Date: July 10, 2003)	Confirmation Number: 5599
)	
Date of Entry into U.S. National Stage: January 10, 2005)	
)	
For: Method for Detection of Bioactive Peptides)	
)	

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Window, **Mail Stop Amendment**
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants petition the Examiner to consider this Information Disclosure Statement and documents listed on the attached Form PTO-1449. To the best of the undersigned's knowledge, this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced Application. Accordingly, Applicants do not believe a fee is due for filing this Information Disclosure Statement.

The documents included in this Information Disclosure Statement (IDS) were cited in an International Search Report dated October 24, 2003 in related application PCT/AU2003/000892. A copy of the search report is attached for the Examiner's convenience.

Applicants respectfully request that the Examiner initial and return the Form PTO-1449, indicating that the information has been considered and made of record herein.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If it should be determined that the listed documents constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such document.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.


Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. §1.136(a)(3).

Respectfully submitted,

MORGAN, LEWIS & BOCKIUS LLP

Dated: July 14, 2006

Morgan, Lewis & Bockius LLP
Customer No. 09629
 1111 Pennsylvania Avenue
 Washington, D.C. 20004
 202-739-3000

By: 
 Elizabeth C. Weimar
 Reg. No. 44,478



Group Art Unit: Not assigned